Dana Taylor

At USA Today Network, we know when the country is focused, people listen closer.

When the spotlight gets brighter, the brands people recognize and trust win.

Will you be one of them?

Show up alongside USA Today Network's year-long USA 250 coverage and place your business in the moments that matter when attention is raised.

Learn how we build familiarity and trust at 250.usatoday.com.

This year isn't just history.

It's your competitive edge.

A growing number of lawsuits allege that the manufacturers of certain GLP-1 drugs like Ozempic, Wegovy, and Manjaro fail to sufficiently warn of the risks of certain severe injuries.

As more adverse experiences come to light, how are drug makers responding to safety concerns?

Hello and welcome to USA Today's The Excerpt.

I'm Dana Taylor.

Today is Wednesday, January 28th, 2026.

Since 2023, roughly 4,200 patients have filed lawsuits challenging the safety of GLP-1s.

Joining me to discuss some of those cases and the response from drug manufacturers is USA Today investigative data reporter Austin Bast.

It's good to have you back on The Excerpt, Austin.

As you reported, the most common medical complaint by far is something known as stomach paralysis.

What is that exactly, Austin?

How does it affect the body?

Another major complaint is intestinal obstructions.

How severe are some of the worst cases?